Bcl-2-like 14 antibody
Principal name
Bcl-2-like 14 antibody
Alternative names for Bcl-2-like 14 antibody
Bcl-G, Bcl2-L-14, BCLG, BCL2L14, Apoptosis facilitator Bcl-2-like protein 14
Ncbi ID
9606, NP_110393.1, NM_030766, NP_620048, NP_620049, NP_110393, NP_080054.1, NM_025778, NM_001024338, NM_138723, NM_138724, NM_138722
Available reactivities
Available hosts
Available applications
Enzyme Immunoassay (E), Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Immunocytochemistry/Immunofluorescence (ICC/IF), Paraffin Sections (P), EPair for Elisa (EPair)
Background of Bcl-2-like 14 antibody
Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain (reviewed in 1 and 2). BH3 domain containing pro-apoptotic proteins, including Bad, Bax, Bid, Bik, and Hrk, form a growing subclass of the Bcl-2 family. A novel BH3 domain containing protein was recently identified and designated Bcl-G (3). The mRNA of Bcl-G encodes 2 isoforms, Bcl-GL, which is widely expressed in multiple tissues, and Bcl-GS, which is only found in testis. The Bcl-GS protein is predominantly localized to cytoplasmic organelles whereas Bcl-GL was distributed throughout the cytosol. Overexpression of either protein induced apoptosis, although Bcl-GS was far more potent than Bcl-GS. Apoptosis induction was dependent on the BH3 domain and could be suppressed by co-expression with the anti-apoptotic Bcl-XL protein (3).
BCL2L14 monoclonal antibody (M01), clone 1F2 Western Blot analysis of BCL2L14 expression in A-549 ( Cat # L025V1 ).
Detection limit for recombinant GST tagged BCL2L14 is approximately 0.03ng/ml as a capture antibody.
Western Blot analysis of BCL2L14 expression in transfected 293T cell line (H00079370-T01) by BCL2L14 MaxPab polyclonal antibody.Lane 1: BCL2L14 transfected lysate(35.97 KDa).Lane 2: Non-transfected lysate.
Pancreas: Formalin-Fixed Paraffin-Embedded (FFPE)
Brain, cerebellum: Formalin-Fixed Paraffin-Embedded (FFPE)
Western Blot analysis of BCL2L14 expression in transfected 293T cell line (H00079370-T02) by BCL2L14 MaxPab polyclonal antibody.Lane 1: BCL2L14 transfected lysate(36.60 KDa).Lane 2: Non-transfected lysate.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
Western blot analysis of anti-Bcl-G BH3 Domain Pab (Cat. #AP11296PU-N) in K562 cell line lysates (35ug/lane). Bcl-G BH3 Domain (arrow) was detected using the purified Pab.
Immunohistochemical staining of mouse testis tissue using BCL2L14 polyclonal antibody ( Cat # PAB12903 ) at 2 µg/ml.
Western blot analysis of BCL2L14 in U-937 cell lysates with BCL2L14 polyclonal antibody ( Cat # PAB12903 ) at ( A ) 2.5 and ( B ) 5 µg/ml.
Western blot analysis of Bcl-G in U937 cell lysates with Bcl-G antibody at (A) 2.5 and (B) 5 ug/ml.
Immunohistochemical staining of mouse testis tissue using Bcl-G antibody at 2 ug/ml.
Immunofluorescence of Bcl-G in Mouse Testis cells with Bcl-G antibody at 10 ug/mL.
Western blot analysis of extracts from Hela cells and HepG2 cells, using BCL2L14 antibody.The lane on the right is treated with the synthesized peptide.
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using (BCL2L14 Antibody) at dilution 1/40, on the right is treated with fusion protein. (Original magnification: ×200)
The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using (BCL2L14 Antibody) at dilution 1/40, on the right is treated with fusion protein. (Original magnification: ×200)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA306135 | Bcl-2-like 14 (C-term) antibody |
||||||
| Rabbit Polyclonal Bcl-G Antibody | |||||||
 |
Rabbit | Purified | Hu, Ms, Rt | E, P, WB |
0.1 mg /
€371.00
|
||
| OriGene Technologies, Inc. | |||||||
 +2 additional images |
|||||||
| TA315784 | Bcl-2-like 14 antibody |
||||||
| Rabbit polyclonal anti-BCL2L14 antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms | E, WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA349545 | Bcl-2-like 14 antibody |
||||||
| Rabbit Polyclonal Anti-BCL2L14 Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu | E, P |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| AP07282PU-N | Bcl-2-like 14 (C-term) antibody |
||||||
 |
Rabbit | Purified | Hu, Ms, Rt | P, WB |
50 µg /
€380.00
|
||
| Acris Antibodies GmbH | |||||||
| +1 additional image |
|||||||
| AP11296PU-N | Bcl-2-like 14 (BH3 Domain) antibody |
||||||
 |
Rabbit | Ig | Purified | Hu, Ms | P, WB |
0.4 ml /
€370.00
|
|
| Acris Antibodies GmbH | |||||||
| +1 additional image |
|||||||
CRISPR
| Catalog No. | Species | Donor Vector | |
|---|---|---|---|
| KN206404 | BCL2L14 - human gene knockout kit via CRISPR |
||
 |
Human | GFP-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN206404BN | BCL2L14 - human gene knockout kit via CRISPR |
||
|
Human | mBFP-Neo |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN206404LP | BCL2L14 - human gene knockout kit via CRISPR |
||
|
Human | Luciferase-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN206404RB | BCL2L14 - human gene knockout kit via CRISPR |
||
|
Human | RFP-BSD |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN302106 | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
|
Mouse | GFP-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN302106BN | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
|
Mouse | mBFP-Neo |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN302106LP | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
|
Mouse | Luciferase-Puro |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
| KN302106RB | Bcl2l14 - mouse gene knockout kit via CRISPR |
||
|
Mouse | RFP-BSD |
1 kit /
€1,290.00
|
| OriGene Technologies, Inc. | |||
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP306404 | Bcl-2-like 14 (transcript variant 1) |
||||
| Recombinant protein of human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 1 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
| OriGene Technologies, Inc. | |||||
|
|||||
| TP315213 | Bcl-2-like 14 (transcript variant 4) |
||||
| Recombinant protein of human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 4 | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€438.00
|
|
| OriGene Technologies, Inc. | |||||
|
|||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY410728 | BCL2L14 overexpression lysate |
|
|
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. | ||
| LY429763 | BCL2L14 overexpression lysate |
|
|
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |
Human Lenti ORF Particles
| Catalog No. | ||
|---|---|---|
| RC206404L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 1, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€989.00
|
|
| OriGene Technologies, Inc. | ||
| RC216333L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 3, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€989.00
|
|
| OriGene Technologies, Inc. | ||
| RC215213L2V | Lenti ORF particles, BCL2L14 (mGFP-tagged) - Human BCL2-like 14 (apoptosis facilitator) (BCL2L14), transcript variant 4, 200 uL, >10^7 TU/mL |
|
|
200 µl /
€989.00
|
|
| OriGene Technologies, Inc. | ||
